Examkin

Patient Management

2074 questions

All types2,074Multiple choice1,048Multiple select393Matching221Ordering412
Question 2061Question →

Six days following a two-vessel coronary artery bypass grafting, a 64-year-old male alerts the nursing staff to acute, severe pain and swelling in his right leg. His postoperative course had previously been uncomplicated. His current medication regimen includes aspirin, atorvastatin, metoprolol succinate, and subcutaneous unfractionated heparin for deep venous thrombosis prophylaxis. Vital signs show a temperature of 37.1°C, blood pressure of 128/78 mm Hg, heart rate of 82/min, and respiratory rate of 16/min. Physical examination demonstrates significant asymmetric right calf swelling with pitting edema, localized erythema, and tenderness to palpation.

Relevant laboratory results are compared to his preoperative baseline:

Laboratory TestPreoperativeCurrent (Day 6)
Hemoglobin14.2 g/dL12.1 g/dL
Platelet count245,000/mm³68,000/mm³
Serum creatinine0.9 mg/dL1.0 mg/dL

A duplex ultrasound of the lower extremities reveals an acute noncompressible thrombus in the right popliteal vein. Which of the following is the most appropriate next step in the pharmacologic management of this patient?

Show answer & explanation

Answer: Discontinue unfractionated heparin and initiate argatroban

Answer

The most appropriate next step is to discontinue unfractionated heparin and initiate a direct thrombin inhibitor, such as argatroban.
This patient presents with a classic presentation of Type 2 Heparin-Induced Thrombocytopenia (HIT), defined by an unexplained drop in platelet count of >50% occurring 5 to 10 days after the initiation of heparin therapy, accompanied by a new thrombotic event (deep vein thrombosis). HIT is driven by IgG antibodies against heparin-platelet factor 4 (PF4) complexes, which activate platelets and create a profoundly prothrombotic state. The absolute first step in pharmacologic management is to discontinue all sources of heparin (including heparin flushes). Because the patient has an active thrombosis and is highly hypercoagulable, alternative systemic anticoagulation must be initiated immediately. Direct thrombin inhibitors (such as argatroban or bivalirudin) or the factor Xa inhibitor fondaparinux are the treatments of choice.

Step-by-Step Solution

1
Interpret the clinical timeline and laboratory values.
The patient experienced a >50% drop in platelet count (from 245,000/mm³ to 68,000/mm³) occurring exactly 6 days after exposure to unfractionated heparin.
Timing and magnitude of the platelet drop are key criteria (4Ts score) for identifying suspected Heparin-Induced Thrombocytopenia (HIT).
2
Assess the new clinical symptoms.
The patient developed a new DVT in the right lower extremity.
HIT is a paradoxically prothrombotic state. The formation of a new clot confirms Heparin-Induced Thrombocytopenia and Thrombosis (HITT).
3
Select the appropriate pharmacologic intervention.
All heparin products must be stopped, and a non-heparin anticoagulant (argatroban, bivalirudin, or fondaparinux) must be initiated.
Ongoing anticoagulation is mandatory due to the acute DVT. Standard agents like LMWH (cross-reactivity) and warfarin (venous gangrene risk) are contraindicated.

Key Concept

Management of Heparin-Induced Thrombocytopenia (HIT) requires the immediate discontinuation of all heparin products and the initiation of a non-heparin anticoagulant (e.g., argatroban) to manage the profoundly hypercoagulable state.
Question 2062Question →

An internal medicine physician is admitting a patient with persistent, highly symptomatic atrial fibrillation. The patient, a septuagenarian with a known history of ischemic cardiomyopathy (left ventricular ejection fraction of 30%30\%), has failed an optimal rate control strategy. Following consultation with electrophysiology, the decision is made to initiate dofetilide for chemical cardioversion and rhythm maintenance.

Which of the following monitoring parameters and baseline assessments are strictly required during the initiation phase of this specific pharmacotherapy? (Select 3 correct answers)

Select all that apply

Show answer & explanation

Answer: Continuous electrocardiographic telemetry for a minimum of 3 days; Baseline and serial assessment of estimated creatinine clearance; Serial measurement of serum potassium and magnesium levels

Answer

The strictly required monitoring parameters are continuous electrocardiographic telemetry, serial assessment of estimated creatinine clearance, and measurement of serum potassium and magnesium levels.
Dofetilide is a potent Class III antiarrhythmic that carries a significant risk of inducing QT interval prolongation and life-threatening Torsades de Pointes (TdP). Due to this specific proarrhythmic risk, regulatory protocols mandate that patients be admitted to a facility equipped with continuous electrocardiographic monitoring (telemetry) for a minimum of 3 days (or 12 hours after electrical cardioversion, whichever is longer) to observe the QTc interval. Furthermore, dofetilide is primarily cleared by the kidneys. Toxic accumulation occurs rapidly in renal impairment, so calculating the creatinine clearance is strictly required prior to the first dose and throughout the initiation phase to appropriately adjust the dosage or withhold the drug if clearance drops below 2020 mL/min. Lastly, hypokalemia and hypomagnesemia act as severe precipitants for TdP; therefore, serial measurement of serum potassium and magnesium levels is mandatory to ensure they remain within the therapeutic range during the loading phase.

Step-by-Step Solution

1
Identify the primary risks of the chosen drug (dofetilide).
Dofetilide is a Class III antiarrhythmic with a potent, dose-dependent risk of QT interval prolongation and Torsades de Pointes.
Understanding the adverse effect profile drives the specific inpatient monitoring requirements.
2
Determine the clearance mechanism of the drug.
Dofetilide is primarily cleared unchanged by the kidneys.
This establishes that baseline renal function (creatinine clearance) must be calculated to adjust the dose or identify contraindications.
3
Identify interacting physiological factors that exacerbate the drug's primary risk.
Low serum potassium and magnesium independently prolong the QT interval.
Maintaining electrolyte homeostasis is critical to preventing fatal arrhythmias during dofetilide initiation.
4
Exclude organ toxicities associated with different antiarrhythmic agents.
Thyroid and hepatic monitoring are excluded, as these are toxicities characteristic of amiodarone, not dofetilide.
Distinguishing between the unique toxicity profiles of antiarrhythmics prevents unnecessary and incorrect testing.

Key Concept

Dofetilide Initiation and Monitoring Protocol
Estimated Time:1m 30s
Question 2063Question →

A 55-year-old man with a history of recurrent major depressive disorder, generalized anxiety disorder, and chronic neuropathic pain is brought to the emergency department by his wife due to confusion, severe agitation, and profuse sweating that began earlier today. His home medications include fluoxetine and gabapentin. Three days ago, he was prescribed tramadol by an orthopedic surgeon for worsening back pain and linezolid by his primary care physician for a suspected methicillin-resistant *Staphylococcus aureus* skin infection. Vital signs are temperature 39.2°C (102.6°F), blood pressure 168/98 mmHg, heart rate 122/min, and respiratory rate 22/min. Physical examination reveals a diaphoretic, agitated man. Neurologic examination shows bilateral hyperreflexia and inducible myoclonus in the lower extremities. Bowel sounds are hyperactive.

Which of the following pharmacologic interventions are appropriate in the immediate management of this patient? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Discontinue fluoxetine, tramadol, and linezolid; Administer intravenous lorazepam

Answer

The appropriate interventions are to immediately discontinue all serotonergic agents (fluoxetine, tramadol, and linezolid) and to administer intravenous lorazepam for symptom control.
The correct interventions involve discontinuing fluoxetine, tramadol, and linezolid, and administering intravenous lorazepam. This patient's presentation of altered mental status, autonomic instability (hyperthermia, tachycardia, hypertension, diaphoresis), and neuromuscular hyperactivity (hyperreflexia and inducible myoclonus) in the context of taking multiple newly prescribed medications confirms the diagnosis of serotonin syndrome. Fluoxetine is a selective serotonin reuptake inhibitor (SSRI), tramadol inhibits serotonin reuptake, and linezolid is an antibiotic that possesses reversible, nonselective monoamine oxidase inhibitor (MAOI) activity. The concomitant use of these drugs profoundly increases intrasynaptic serotonin levels. The cornerstone of acute management is the immediate discontinuation of all serotonergic agents. Additionally, intravenous benzodiazepines (such as lorazepam or diazepam) are the primary pharmacologic therapy used to control agitation, tremor, and autonomic instability.

Step-by-Step Solution

1
Identify the patient's toxidrome based on clinical findings.
The patient exhibits altered mental status, autonomic hyperactivity (fever, tachycardia, hypertension, diaphoresis), and neuromuscular excitability (hyperreflexia, myoclonus).
Recognizing the classic triad of symptoms is essential for diagnosing serotonin syndrome and distinguishing it from other toxidromes.
2
Analyze the patient's recent medication history for interacting agents.
The patient is taking fluoxetine (SSRI), tramadol (SNRI/opioid), and linezolid (an antibiotic that also acts as a nonselective MAOI).
The combination of these multiple serotonergic mechanisms (reuptake inhibition and decreased breakdown) precipitated the severe serotonin toxicity.
3
Determine the appropriate immediate pharmacologic management steps.
Immediate discontinuation of all offending agents and administration of supportive care with benzodiazepines.
Removing the pharmacologic triggers halts further toxicity, while benzodiazepines effectively control agitation, seizures, and hyperdynamic vital signs.

Key Concept

The recognition and acute management of serotonin syndrome, emphasizing the immediate discontinuation of all serotonergic agents (including unexpected culprits like linezolid and tramadol) and the initiation of supportive care with benzodiazepines.
Question 2064Question →

A 6262-year-old man with a history of alcohol-associated cirrhosis is evaluated in the hospital on day 33 of admission. He was initially brought to the emergency department by his wife due to increasing lethargy, confusion, and an altered sleep-wake cycle over the preceding 4848 hours. On admission, he had not had a bowel movement for four days. Initial examination revealed marked disorientation to time and place, and pronounced asterixis. Laboratory studies on admission showed a serum ammonia level of 135μmol/L135 \mu mol/L (normal: 15−45μmol/L15-45 \mu mol/L) and an International Normalized Ratio (INR) of 1.71.7. He was admitted and promptly started on oral lactulose.

Today, the patient is awake, alert, and fully oriented. He is interacting appropriately with the medical staff. He no longer exhibits asterixis. He reports having three soft bowel movements over the past 2424 hours. Vital signs are within normal limits. A repeat basic metabolic panel is unremarkable, his INR is 1.61.6, and his serum ammonia level is 118μmol/L118 \mu mol/L.

Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Maintain the current lactulose regimen without dosage modification.

Answer

Maintain the current lactulose regimen without dosage modification.
The correct action is to maintain the current lactulose regimen without modification. The monitoring and treatment evaluation of hepatic encephalopathy relies primarily on clinical assessment rather than laboratory values. The therapeutic goal of lactulose is two-fold: achieving clinical resolution of altered mental status (and associated signs like asterixis) and producing 22 to 33 soft bowel movements daily to facilitate the excretion of nitrogenous waste. This patient is fully oriented and is experiencing the target number of bowel movements. Although his serum ammonia level remains elevated, ammonia levels correlate poorly with the degree of encephalopathy in chronic liver disease and should not be used as a target for therapy titration. Therefore, the current regimen is optimal and should be continued as maintenance therapy.

Step-by-Step Solution

1
Evaluate the patient's clinical response to the current therapy.
The patient's mental status has normalized, and asterixis has completely resolved.
Clinical presentation (mental status and physical exam findings) is the primary indicator of hepatic encephalopathy resolution.
2
Evaluate the patient's physiological response to the medication dosing.
The patient is having three soft bowel movements daily.
The therapeutic goal of lactulose is to produce 2 to 3 soft bowel movements per day to ensure adequate gut ammonia excretion without causing profound volume depletion.
3
Determine the necessary intervention based on the clinical evaluation.
Maintain the current therapeutic regimen.
The patient has achieved optimal clinical and physiological therapeutic responses, rendering dosage changes or further diagnostic workup unnecessary despite the persistent elevation in serum ammonia.

Key Concept

The management of hepatic encephalopathy is guided by the patient's clinical status and bowel movement frequency (target of 2-3 daily), not by serum ammonia levels.
Estimated Time:1m 30s
Question 2065Question →

Following an emergency laparotomy for a perforated viscus, a 58-year-old male is transferred to the intensive care unit. He is intubated, sedated, and receiving broad-spectrum intravenous antibiotics. Despite the rapid administration of a 30 mL/kg intravenous crystalloid fluid bolus, his blood pressure remains 70/40 mmHg with a mean arterial pressure (MAP) of 50 mmHg. His extremities are warm to the touch, and bedside echocardiography demonstrates a hyperdynamic left ventricle. Arrange the following pharmacologic interventions in the most appropriate sequential order for escalating hemodynamic support in this patient, assuming he continuously fails to achieve the target MAP of ≥65\geq 65 mmHg after the implementation of each preceding step.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequential order for escalating hemodynamic support in refractory septic shock is: 1) Norepinephrine, 2) Vasopressin, 3) Epinephrine, 4) Hydrocortisone.
According to the Surviving Sepsis Campaign guidelines, the pharmacologic management of septic shock unresponsive to initial fluid resuscitation follows a strict escalation protocol. Norepinephrine is the first-line vasopressor. If the MAP remains below 6565 mmHg, vasopressin is added as a second-line agent to spare catecholamine doses. If the patient remains hypotensive despite both norepinephrine and vasopressin, epinephrine is added as a third-line vasopressor. Finally, in patients with an ongoing requirement for vasopressor therapy despite these escalating steps, intravenous hydrocortisone is indicated to address critical illness-related corticosteroid insufficiency and improve vascular responsiveness.

Step-by-Step Solution

1
Evaluate the response to initial fluid resuscitation.
The patient remains profoundly hypotensive (MAP < 65 mmHg) despite receiving an adequate 30 mL/kg crystalloid fluid bolus.
Vasopressors are indicated when fluid resuscitation fails to restore adequate perfusion and MAP.
2
Select and initiate the first-line vasopressor.
Norepinephrine is started as the primary vasoactive agent.
Norepinephrine provides balanced alpha and beta adrenergic stimulation, effectively increasing systemic vascular resistance with less risk of tachyarrhythmias compared to dopamine or pure epinephrine.
3
Escalate to a second-line agent if the MAP target is not met.
Vasopressin is added to the ongoing norepinephrine infusion.
Adding vasopressin acts via non-catecholamine receptors (V1) to increase vascular tone, which helps achieve the MAP target while sparing the need for excessively high, toxic doses of norepinephrine.
4
Escalate to a third-line agent if shock remains refractory.
Epinephrine is added to the regimen.
Epinephrine provides additional potent inotropic and chronotropic support, but is reserved as a third-line agent due to its potential to cause tachyarrhythmias and splanchnic ischemia.
5
Consider adjunctive non-vasopressor therapy.
Intravenous hydrocortisone is administered.
Corticosteroids treat potential critical illness-related corticosteroid insufficiency and help restore vascular responsiveness to catecholamines in patients with an ongoing requirement for vasopressor therapy.

Key Concept

Sequential Pharmacologic Escalation in Septic Shock
Estimated Time:1m 30s
Question 2066Question →

A 4545-year-old man comes to the office to establish care. He has not seen a physician in over a decade. The patient feels well and has no acute complaints. Medical history is notable for asthma, for which he uses an albuterol inhaler as needed. He has smoked 11 pack of cigarettes daily for the past 25 years. He drinks alcohol occasionally. Family history is significant for a father who died of a myocardial infarction at age 70. Vital signs are temperature 37.0∘C37.0^\circ\text{C} (98.6∘F98.6^\circ\text{F}), blood pressure 122/80122/80 mm Hg, pulse 7676/min, and respirations 1414/min. Body mass index is 29 kg/m229 \text{ kg/m}^2. Physical examination reveals a well-appearing man. The lungs are clear to auscultation bilaterally. Cardiac examination shows a regular rate and rhythm without murmurs. Which of the following preventive interventions are indicated for this patient at this time? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Screening for colorectal cancer; Screening for hepatitis C virus infection; Administration of 20-valent pneumococcal conjugate vaccine

Answer

The correct interventions are screening for colorectal cancer, screening for hepatitis C virus infection, and administration of the 20-valent pneumococcal conjugate vaccine.
This patient requires three specific preventive interventions based on his age, medical history, and lack of prior care. First, the USPSTF recommends average-risk screening for colorectal cancer beginning at age 45. Second, a one-time screening for hepatitis C virus infection is recommended for all adults aged 18 to 79. Finally, the ACIP recommends pneumococcal vaccination for adults aged 19 to 64 with chronic medical conditions; his history of asthma fulfills this criterion, making the 20-valent pneumococcal conjugate vaccine indicated.

Step-by-Step Solution

1
Evaluate the patient's age-based screening requirements.
The patient is 45 years old, which is the exact starting age for average-risk colorectal cancer screening.
Current USPSTF guidelines recommend starting colorectal cancer screening at age 45 to reduce mortality.
2
Assess the patient for infectious disease screening indications.
He has no record of prior hepatitis C virus (HCV) testing. All adults aged 18 to 79 should receive one-time HCV screening.
HCV infection is often asymptomatic, and early detection and treatment prevent long-term complications such as cirrhosis and hepatocellular carcinoma.
3
Determine immunization needs based on age and comorbid conditions.
The patient has a diagnosis of asthma.
Asthma increases the risk of severe pneumococcal disease, making it a qualifying indication for pneumococcal vaccination in adults aged 19 to 64.
4
Review the patient's smoking history for specific screening indications.
He has a 25 pack-year smoking history but is only 45 years old.
Both lung cancer screening (starting at age 50) and abdominal aortic aneurysm screening (starting at age 65) are not yet indicated due to his young age, despite his heavy smoking history.

Key Concept

Evidence-based preventive care requires tailoring screening and immunization recommendations based on age, chronic medical conditions (e.g., asthma), and specific risk factors (e.g., smoking history).
Question 2067Question →

A 54-year-old man visits the outpatient clinic for a scheduled assessment. He underwent a mechanical aortic valve replacement three years ago. His daily medications include warfarin and low-dose aspirin. Over the past month, the patient has felt a persistent low mood and decided to start taking an over-the-counter herbal supplement, St. John's wort. He reports no episodes of bleeding, bruising, chest discomfort, or dyspnea. Vital signs are within normal limits. Cardiovascular examination demonstrates a crisp prosthetic valve click with no murmurs. Today, his International Normalized Ratio (INR) is 1.4; his previous value four weeks ago was 2.6. Which of the following is the most appropriate next step in the management of this patient?

Show answer & explanation

Answer: Counsel the patient to discontinue the herbal supplement and repeat the INR in one week

Answer

Counsel the patient to discontinue the herbal supplement and repeat the INR in one week
The correct action is to advise the patient to stop taking St. John's wort and to recheck the INR in one week. Patients with a mechanical aortic valve require lifelong anticoagulation with a target INR of 2.0 to 3.0. St. John's wort is a well-known inducer of several cytochrome P450 enzymes, notably CYP2C9 and CYP3A4. Because warfarin is primarily metabolized by CYP2C9, induction of this enzyme increases warfarin clearance, significantly reducing its serum concentration and clinical effect. This manifests as a subtherapeutic INR, placing the patient at increased risk for valve thrombosis and systemic embolization. The most appropriate and direct intervention is to remove the interacting agent. Since the synthesis and half-lives of vitamin K-dependent clotting factors take several days to equilibrate, repeating the INR in approximately one week is the standard protocol to verify that the INR is rising back into the therapeutic range.

Step-by-Step Solution

1
Analyze the patient's presentation and laboratory findings.
The patient has a mechanical aortic valve (target INR 2.0-3.0) and presents with a subtherapeutic INR of 1.4.
Identifying the deviation from the therapeutic target is the first step in recognizing the clinical problem.
2
Identify the cause of the subtherapeutic INR.
The patient recently started St. John's wort, which is a known potent inducer of hepatic cytochrome P450 enzymes.
Determining the etiology of the lab abnormality directs the management approach.
3
Determine the most appropriate management.
Discontinue the offending agent (St. John's wort) and recheck the INR in approximately one week to ensure it returns to the therapeutic range.
Removing the interacting drug will reverse the enhanced metabolism of warfarin without unnecessarily exposing the patient to other invasive interventions or contraindicated medications.

Key Concept

St. John's wort is a potent inducer of cytochrome P450 enzymes (including CYP2C9 and CYP3A4), which accelerates the metabolism of warfarin, leading to a subtherapeutic International Normalized Ratio (INR).
Question 2068Question →

A 64-year-old man with metastatic non-small cell lung cancer develops severe diarrhea (up to 10 watery stools daily) and abdominal cramping 4 weeks after initiating pembrolizumab therapy. His symptoms are classified as severe (Grade 3) immune-mediated colitis after infectious etiologies are ruled out and a colonoscopy confirms the diagnosis. He is admitted to the hospital for acute management. Arrange the following steps in the correct evidence-based sequence for the treatment, monitoring, and therapeutic de-escalation of this patient's condition.

Drag items to arrange them in the correct order

Show answer & explanation

Answer

The correct sequence begins with stopping the checkpoint inhibitor and starting high-dose intravenous corticosteroids, followed by a 48 to 72-hour monitoring period. Due to a lack of improvement, a biologic agent (infliximab) is administered, after which the patient is transitioned to oral steroids upon symptom resolution, followed finally by a slow 4 to 6-week taper.
The evidence-based sequence for severe (Grade 3 or 4) immune-mediated colitis starts with permanent discontinuation of the offending agent alongside high-dose intravenous corticosteroids. A critical monitoring window of 48 to 72 hours follows to assess steroid responsiveness. If symptoms are refractory, therapy is escalated to a biologic agent (e.g., infliximab). Once symptoms improve to Grade 1, intravenous steroids are transitioned to oral forms, which must then be tapered very gradually over 4 to 6 weeks to prevent rebound flares.

Step-by-Step Solution

1
Identify the severity and initiate first-line therapy.
Pembrolizumab is discontinued and high-dose intravenous methylprednisolone is started.
Grade 3 immune-mediated colitis requires immediate cessation of the offending agent and profound immunosuppression to halt the autoimmune response.
2
Establish a monitoring timeframe.
The patient is closely observed for 48 to 72 hours.
This is the standard clinical window to determine if the immune-related adverse event is steroid-responsive or steroid-refractory.
3
Escalate therapy for steroid-refractory disease.
Infliximab is administered.
Failure to improve within 48 to 72 hours on high-dose steroids necessitates the addition of a biologic agent like a TNF-alpha inhibitor.
4
De-escalate to oral therapy upon improvement.
Intravenous steroids are switched to oral prednisone.
Once symptoms improve to Grade 1 or baseline, parenteral therapy is no longer required and oral transition facilitates outpatient management.
5
Implement a long-term taper.
Corticosteroids are tapered over 4 to 6 weeks.
Rapid withdrawal of corticosteroids can lead to a severe rebound flare of the immune-mediated adverse event.

Key Concept

Management of severe immune checkpoint inhibitor-mediated colitis involves immediate cessation of the drug, initiation of high-dose corticosteroids, monitoring for 48 to 72 hours, escalation to biologic therapy if refractory, and a subsequent slow corticosteroid taper.
Question 2069Question →

Presenting to a new ambulatory care practice, a 60-year-old woman requests a comprehensive health review. She recently relocated to the area and brought her complete medical dossier for continuity of care. Her past medical history is notable for essential hypertension, currently well-controlled on amlodipine. She reports a history of smoking one pack of cigarettes daily from age 20 to 52, but she completely stopped 8 years ago. She consumes alcohol on rare social occasions and exercises moderately three times a week.

A review of her records reveals the following timeline of preventive interventions:
- Colonoscopy at age 52 (8 years ago) revealed no polyps or abnormalities.
- Mammography at age 58 (2 years ago) was interpreted as Breast Imaging Reporting and Data System (BI-RADS) category 1.
- Papanicolaou (Pap) test with human papillomavirus (HPV) co-testing at age 57 (3 years ago) was negative.
- Tetanus, diphtheria, and pertussis (Tdap) vaccine was administered at age 52.
- Influenza vaccine was administered 2 months ago at a community pharmacy.
- She has no history of receiving any formulation of the zoster vaccine.

Her body mass index is 24 kg/m². Vital signs today are within normal limits, and the physical examination is unremarkable. Based on the current United States Preventive Services Task Force (USPSTF) and Advisory Committee on Immunization Practices (ACIP) recommendations, which of the following preventive interventions are definitively indicated to be ordered or administered for this patient at today's visit? (Select all that apply)

Select all that apply

Show answer & explanation

Answer: Low-dose chest computed tomography; Screening mammography; Recombinant zoster vaccine

Answer

The definitively indicated interventions are low-dose chest computed tomography, screening mammography, and the recombinant zoster vaccine.
The correct interventions integrate multiple overlapping preventive guidelines. Low-dose chest computed tomography is indicated because the patient fits the USPSTF criteria for lung cancer screening (age 50-80, ≥20 pack-year history, and current smoker or quit within the last 15 years). Screening mammography is indicated because the USPSTF recommends biennial screening starting at age 40, and her last exam was 2 years ago. The recombinant zoster vaccine is indicated because ACIP recommends two doses for all immunocompetent adults starting at age 50, and she has never received it.

Step-by-Step Solution

1
Evaluate cancer screening indications based on patient age and specific risk factors.
The patient is 60 years old. She requires biennial mammography (due now, as her last was 2 years ago). She also requires annual lung cancer screening with low-dose CT because she is between 50-80, has >20 pack-years of smoking history (32 pack-years), and quit less than 15 years ago (quit 8 years ago). Colon cancer screening is up to date (normal 8 years ago; next due at 10 years). Cervical cancer screening is up to date (negative co-test 3 years ago; next due at 5 years).
To apply age- and risk-appropriate USPSTF guidelines for breast, lung, colorectal, and cervical cancer.
2
Assess immunization requirements according to the adult ACIP schedule.
The patient requires the recombinant zoster vaccine (indicated for all adults 50 and older). Pneumococcal vaccine is not indicated as she is under 65 and a former (not current) smoker without other qualifying risk factors. Tdap and influenza are up to date.
To ensure immunity against preventable infectious diseases while avoiding non-indicated vaccines.
3
Review bone mineral density screening criteria.
The patient is under 65 without high-risk factors for osteoporosis, so dual-energy x-ray absorptiometry (DEXA) is not indicated.
To avoid unnecessary diagnostic imaging and downstream costs.

Key Concept

Integration of age-appropriate and risk-based preventive screening and immunization guidelines for adults.
Question 2070Question →

A primary care physician is reviewing the charts of several adult patients scheduled for routine health maintenance visits. Based on current guidelines, match each patient's clinical profile with the most appropriate, immediate preventive intervention.

Click a left item, then click its matching right item

Items

A 66-year-old healthy woman whose last Papanicolaou test with high-risk human papillomavirus co-testing was normal at age 63; she has never sustained a fracture.
A 52-year-old man of Asian descent with a body mass index of 23.5 kg/m2 who feels well; his blood pressure is 120/78 mmHg.
A 72-year-old man with a 30 pack-year smoking history who successfully quit 12 years ago; he has never undergone dedicated pulmonary imaging.
A 26-year-old healthy woman with no personal medical history; her older sister was recently identified as a carrier of a pathogenic BRCA1 gene mutation.

Matches

Show answer & explanation

Answer

Match the 66-year-old woman with a dual-energy x-ray absorptiometry scan. Match the 52-year-old Asian man with abnormal blood glucose screening. Match the 72-year-old former smoker with low-dose computed tomography. Match the 26-year-old woman with a sister having a BRCA1 mutation to the familial risk assessment tool.
Each patient's clinical profile perfectly aligns with a specific, strongly recommended preventive service based on current US Preventive Services Task Force guidelines regarding age, sex, ethnicity, family history, and smoking status.

Step-by-Step Solution

1
Evaluate the 66-year-old woman's preventive care needs.
She requires a dual-energy x-ray absorptiometry scan.
All women aged 65 and older should be screened for osteoporosis. Routine cervical cancer screening is no longer indicated for her.
2
Evaluate the 52-year-old Asian man's preventive care needs.
He requires blood glucose screening.
His body mass index of 23.5 kg/m2 classifies him as overweight according to the specific criteria for Asian Americans, warranting diabetes screening.
3
Evaluate the 72-year-old former smoker's preventive care needs.
He requires low-dose computed tomography of the chest.
He meets the criteria for lung cancer screening: age 50-80, at least 20 pack-years, and quit within the last 15 years.
4
Evaluate the 26-year-old woman's preventive care needs regarding her sister's BRCA1 mutation.
She requires a familial risk assessment tool.
First-degree relatives of known BRCA mutation carriers must be assessed to determine if genetic counseling and subsequent testing are appropriate.

Key Concept

Application of US Preventive Services Task Force (USPSTF) guidelines for diverse adult populations, adjusting for demographic-specific risk factors such as age, ethnicity, and family history.
Question 2071Question →

An independent 68-year-old resident of a senior living community presents to the ambulatory care clinic reporting two days of painful urination and severe urinary urgency. She notes lower pelvic pressure but denies fevers, chills, vaginal discharge, or back pain. Her medical history is significant for seropositive rheumatoid arthritis, hypertension, and stage 4 chronic kidney disease secondary to hypertensive nephrosclerosis. Her daily medications include amlodipine and folic acid, and she takes methotrexate once weekly. Vital signs are within normal limits. Physical examination reveals mild suprapubic tenderness without costovertebral angle tenderness.

Laboratory results:
Serum creatinine: 2.3 mg/dL
Estimated GFR: 24 mL/min/1.73 m²

Urinalysis:
Appearance: Cloudy
Specific gravity: 1.018
pH: 6.5
Leukocyte esterase: Positive
Nitrite: Negative
Protein: Trace
WBC: 25-30/hpf
RBC: 1-2/hpf
Bacteria: Moderate

Which of the following is the most appropriate next step in pharmacologic management?

Show answer & explanation

Answer: Prescribe oral cephalexin

Answer

Prescribe oral cephalexin
The correct answer is to prescribe oral cephalexin. The patient presents with classic symptoms of acute uncomplicated cystitis supported by urinalysis demonstrating pyuria. Standard first-line empiric treatments for uncomplicated cystitis include nitrofurantoin, trimethoprim-sulfamethoxazole (TMP-SMX), and fosfomycin. However, this patient's complex medical history restricts standard choices. Nitrofurantoin is contraindicated in patients with an estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m² because it will not achieve adequate therapeutic concentrations in the bladder and poses a higher risk of systemic toxicity. TMP-SMX is absolutely contraindicated due to her concurrent use of methotrexate; both medications act as folate antagonists, and their co-administration can precipitate profound, life-threatening pancytopenia. Consequently, an alternative second-line agent must be used. Oral beta-lactams, such as cephalexin, cefpodoxime, or amoxicillin-clavulanate, are safe and effective alternatives in this setting.

Step-by-Step Solution

1
Diagnose the clinical condition
The patient has acute uncomplicated cystitis based on dysuria, urgency, suprapubic pain, and pyuria.
Establishing the diagnosis dictates the initial choice of empiric antimicrobial therapy.
2
Evaluate first-line therapies against patient comorbidities
Nitrofurantoin is ruled out due to stage 4 CKD (eGFR 24 mL/min). Trimethoprim-sulfamethoxazole is ruled out due to concurrent methotrexate use.
First-line therapies carry absolute or relative contraindications in specific medically complex populations.
3
Select the best alternative agent
Oral cephalexin (or another appropriate beta-lactam) is selected.
Beta-lactams are safe in CKD (with appropriate dose adjustment) and do not have major pharmacodynamic interactions with methotrexate.

Key Concept

Empiric antimicrobial selection must account for renal function and potentially fatal drug-drug interactions, such as the synergistic bone marrow suppression caused by co-administration of methotrexate and trimethoprim-sulfamethoxazole.
Estimated Time:1m 30s
Question 2072Question →

A 62-year-old man is evaluated in the cardiac intensive care unit after undergoing primary percutaneous coronary intervention (PCI) for an acute anterior ST-segment elevation myocardial infarction. A drug-eluting stent was successfully deployed in the proximal left anterior descending artery. His past medical history is significant for hypertension, hyperlipidemia, type 2 diabetes mellitus, and a transient ischemic attack 2 years ago that presented as right-sided weakness resolving completely within 12 hours.

Vital signs are temperature 37.1°C (98.8°F), blood pressure 118/76 mm Hg, pulse 74/min, and respirations 14/min. Physical examination reveals a normal S1 and S2 with no murmurs, clear lungs to auscultation, and no peripheral edema.

His current medications include intravenous unfractionated heparin, chewable aspirin, high-intensity atorvastatin, and intravenous nitroglycerin. Laboratory studies show a serum creatinine of 1.1 mg/dL, potassium 4.2 mEq/L, and normal platelet count.

The cardiology team is discussing the initiation of a P2Y12 receptor inhibitor to complete his dual antiplatelet therapy regimen. The resident suggests starting prasugrel.

Which of the following features of this patient's clinical profile represents an absolute contraindication to the use of this specific pharmacologic intervention?

Show answer & explanation

Answer: History of transient ischemic attack

Answer

History of transient ischemic attack
The correct answer is the patient's history of transient ischemic attack. Prasugrel is a potent thienopyridine P2Y12 receptor inhibitor used as part of dual antiplatelet therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. However, it carries a black-box warning and is absolutely contraindicated in patients with a history of transient ischemic attack (TIA) or stroke. This contraindication is based on trial data showing a significantly increased risk of major bleeding, particularly fatal intracranial hemorrhage, in this subgroup.

Step-by-Step Solution

1
Identify the patient's clinical situation and the proposed pharmacologic intervention.
The patient is post-PCI for an acute myocardial infarction, and the team proposes initiating prasugrel for dual antiplatelet therapy.
Establishing the clinical context is essential for evaluating the safety and appropriateness of the proposed drug.
2
Review the patient's medical history for potential contraindications to prasugrel.
The medical history includes hypertension, hyperlipidemia, type 2 diabetes mellitus, and a transient ischemic attack (TIA).
Prasugrel carries specific black-box warnings that must be cross-referenced with the patient's comorbidities prior to prescription.
3
Apply pharmacological knowledge regarding prasugrel's contraindications.
Prasugrel is absolutely contraindicated in patients with a prior TIA or stroke.
Clinical trials demonstrated an unacceptably high risk of fatal intracranial hemorrhage when prasugrel is used in patients with a history of cerebrovascular ischemic events.

Key Concept

Prasugrel is absolutely contraindicated in patients with a history of transient ischemic attack (TIA) or stroke due to a high risk of fatal intracranial hemorrhage.
Estimated Time:1m 0s
Question 2073Question →

A 55-year-old woman with a mechanical mitral valve presents to the outpatient clinic reporting two days of dysuria, urinary frequency, and suprapubic discomfort. She is currently on a stable regimen of warfarin. Her most recent international normalized ratio (INR) from two weeks ago was 3.1 (target range 2.5 to 3.5). A point-of-care urinalysis is positive for leukocyte esterase and nitrites. The physician diagnoses an uncomplicated lower urinary tract infection and prescribes a 3-day course of trimethoprim-sulfamethoxazole. Which of the following is the most appropriate next step in the management of this patient's anticoagulation therapy?

Show answer & explanation

Answer: Empirically reduce the warfarin dose and measure the international normalized ratio in 3 to 5 days

Answer

Empirically reduce the warfarin dose and measure the international normalized ratio in 3 to 5 days
The correct approach involves recognizing that trimethoprim-sulfamethoxazole (TMP-SMX) is a strong inhibitor of CYP2C9, the primary enzyme responsible for clearing the more potent S-enantiomer of warfarin. When these two drugs are co-administered, warfarin levels rise significantly, leading to a supratherapeutic INR and an increased risk of bleeding. The standard of care for monitoring and treatment evaluation in this scenario is to preemptively reduce the warfarin dose by 25% to 50% and closely monitor the INR by rechecking it within 3 to 5 days. This proactive strategy maintains the patient within the therapeutic window safely.

Step-by-Step Solution

1
Identify the pharmacokinetic interaction between the prescribed medications.
Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 2C9 enzyme, which metabolizes the active S-enantiomer of warfarin.
Recognizing drug-drug interactions is critical before starting new therapies in patients on narrow-therapeutic-index medications like warfarin.
2
Determine the necessary clinical intervention to mitigate risk.
The warfarin dose must be preemptively reduced (typically by 25% to 50%) to account for the decreased clearance.
Waiting for the INR to rise before intervening exposes the patient to an unacceptable risk of hemorrhage.
3
Establish the appropriate timeline for laboratory monitoring.
The INR should be rechecked in 3 to 5 days.
It takes several days for the altered metabolism to fully reflect on the INR, making a 3 to 5 day window ideal for catching early fluctuations.

Key Concept

Pharmacokinetic interactions of warfarin and proactive laboratory monitoring
Estimated Time:1m 0s
Question 2074Question →

A 32-year-old woman comes to the clinic for a routine follow-up visit. Four weeks ago, she was diagnosed with active pulmonary tuberculosis and began a regimen of isoniazid, rifampin, pyrazinamide, ethambutol, and pyridoxine. Today, she reports that her cough and night sweats have completely resolved. She feels well and specifically denies any fatigue, anorexia, nausea, vomiting, abdominal pain, or dark urine. She does not consume alcohol and takes no other medications. Her temperature is 37.1°C (98.8°F), blood pressure is 118/76 mm Hg, and pulse is 72/min. Physical examination shows no scleral icterus, and the abdomen is soft and non-tender without hepatomegaly.

Laboratory studies obtained today show:

Laboratory TestResultReference Range
Total bilirubin0.9 mg/dL0.1–1.2 mg/dL
Aspartate aminotransferase (AST)165 U/L8–40 U/L
Alanine aminotransferase (ALT)180 U/L7–56 U/L
Alkaline phosphatase88 U/L44–147 U/L

Prior to initiating therapy, her AST was 22 U/L and ALT was 24 U/L.

Which of the following is the most appropriate next step in management?

Show answer & explanation

Answer: Continue the current medication regimen and repeat liver function tests in 1 to 2 weeks

Answer

Continue the current medication regimen and repeat liver function tests in 1 to 2 weeks
The correct answer is to continue the current medication regimen and monitor. This patient has asymptomatic drug-induced hepatotoxicity from her tuberculosis treatment. Mild to moderate elevations in transaminases occur in up to 20% of patients on isoniazid, rifampin, and pyrazinamide. Guidelines state that these hepatotoxic medications should be discontinued only if transaminases are greater than 5 times the upper limit of normal (ULN) in an asymptomatic patient, or greater than 3 times the ULN in a patient with symptoms of hepatitis (e.g., anorexia, nausea, abdominal pain, jaundice). This patient's transaminases are elevated (AST is roughly 4 times ULN; ALT is roughly 3 times ULN), but they are strictly less than 5 times the ULN, and she is completely asymptomatic. Therefore, the best next step is to continue the current regimen and repeat liver function tests in 1 to 2 weeks to ensure they do not exceed the toxicity threshold.

Step-by-Step Solution

1
Evaluate the patient's clinical presentation and laboratory results.
The patient is completely asymptomatic, but AST (165 U/L) and ALT (180 U/L) are elevated above baseline.
To determine the severity of drug-induced liver injury caused by the tuberculosis medications.
2
Calculate the magnitude of transaminase elevation relative to the upper limit of normal (ULN).
AST (165) is approximately 4.1 times the ULN (40). ALT (180) is approximately 3.2 times the ULN (56). Both are greater than 3x ULN but less than 5x ULN.
Treatment thresholds for hepatotoxicity are based on strict multiples of the ULN.
3
Apply the management guidelines for tuberculosis drug-induced hepatotoxicity.
Since the enzymes are < 5x ULN and the patient has no symptoms of hepatitis, the criteria to discontinue therapy are not met. The regimen should be continued with repeat testing.
Premature cessation of therapy risks treatment failure; mild asymptomatic elevations often resolve spontaneously.

Key Concept

Management of tuberculosis drug-induced hepatotoxicity
PreviousPage 104 / 104
Patient Management Practice Questions — USMLE Step 3 — Page 104 | Examkin